Journal
PEDIATRIC INFECTIOUS DISEASE JOURNAL
Volume 28, Issue 2, Pages 159-161Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/INF.0b013e3181861d8b
Keywords
HIV; pharmacokinetics; lopinavir/ritonavir; efavirenz
Categories
Funding
- National Institute of Allergy and Infectious Diseases [U01AI068632]
Ask authors/readers for more resources
The pharmacokinetics of lopinavir/ritonavir (LPV/RTV) 300 mg/m(2) twice daily and efavirenz (EFV) 350 mg/m(2) once daily were evaluated in HIV-infected children. The minimum concentrations for LPV contained values above the target range, and the estimated minimum concentrations for EFV contained values below the range. Our data support the current LPV/RTV dose, but EFV 350 mg/m(2) may not be sufficient.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
